CSL Limited (OTCMKTS:CSLLY - Get Free Report) shares reached a new 52-week low during trading on Monday . The stock traded as low as $75.70 and last traded at $79.07, with a volume of 116648 shares traded. The stock had previously closed at $78.95.
Analysts Set New Price Targets
Separately, The Goldman Sachs Group upgraded CSL to a "strong-buy" rating in a research note on Thursday, January 16th.
Check Out Our Latest Report on CSL
CSL Stock Performance
The company's fifty day simple moving average is $81.63 and its 200-day simple moving average is $88.84. The company has a quick ratio of 0.97, a current ratio of 2.18 and a debt-to-equity ratio of 0.58.
CSL Company Profile
(
Get Free Report)
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Articles
Before you consider CSL, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CSL wasn't on the list.
While CSL currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
